What is Alltrna?
Alltrna is a Flagship Pioneering company dedicated to unlocking the potential of transfer RNA (tRNA) biology. The company is pioneering tRNA medicines, a novel therapeutic modality aimed at precisely regulating the protein universe to resolve a wide spectrum of diseases. By leveraging deep insights into tRNA's role in protein synthesis, Alltrna seeks to address previously intractable medical conditions.
How much funding has Alltrna raised?
Alltrna has raised a total of $109M across 1 funding round:
Series B
$109M
Series B (2023): $109M with participation from Flagship Pioneering
Key Investors in Alltrna
Flagship Pioneering
Flagship Pioneering is an American life sciences venture capital company that invests in biotechnology, life sciences, health, and sustainability companies, likely providing strategic guidance and capital for early-stage innovation.
What's next for Alltrna?
The substantial enterprise-level funding and recent strategic investment position Alltrna for accelerated growth and the advancement of its innovative therapeutic pipeline. This capital infusion is expected to fuel further research and development, clinical trials, and the scaling of its platform. The company's focus on tRNA biology represents a cutting-edge approach in the biopharmaceutical landscape, suggesting a trajectory towards significant clinical and commercial impact.
See full Alltrna company page
